Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...

For the past three decades, collaborations, deals and best practice exchanges on innovation and commercialisation have been a ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and antibodies.

SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery ...

The expansion comes just days after Lilly signed a $415m licensing agreement for ATLX-1282, Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis and other neurodegenerative ...

He previously served as Chief Business Officer at Alchemab Therapeutics and TScan ... Earlier in his career, he spent over a decade at Eli Lilly and Company in Search & Evaluation and ...

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

Jane Osbourn, CEO of Alchemab, said ... 3 Big news is also expected from some of the major players; for example, Eli Lilly is aiming to conclude a phase III trial of an oral GLP-1 drug ...